Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

imsidolimab

A humanized monoclonal antibody directed against the interleukin-36 receptor (IL-36R), with potential anti-inflammatory and immunomodulatory activities. Upon administration, imsidolimab targets, binds to and prevents the activity of IL-36R by the pro-inflammatory cytokine IL-36. This prevents IL-36/IL-36R-mediated signaling pathways. This may inhibit skin inflammation in which the IL-36/IL-36R plays a key role. IL-36 is highly upregulated in certain skin inflammatory conditions.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Code name:	ANB019

imsidolimab

Search NCI's Drug Dictionary